Biopolym. Cell. 2004; 20(5):402-409.
http://dx.doi.org/10.7124/bc.0006C2
Структура та функції біополімерів
Загальна організація фібронектинів і їхня роль у нормі та при патології
1Лутай Н. В., 1Бразалук О. З., 1Пелешенко Г. Б., 1Шевцова А. І.
  1. Дніпропетровська державна медична академія
    вул. Дзержинського, 9, Дніпропетровськ, Україна, 49044

Abstract

Зроблено огляд даних щодо структури, функцій і клініко-діагностичної значущості фібронектинів (ФН). ФН – це висо­ко молекулярний глікопротеїн, присутній в екстрацелюлярному матриксі та в різних рідинах тіла, у тому числі в плазмі. Існує декілька ізоформ ФН, утворених повторюваними субодиницями, які складають функціональні домени, що зв'язу­ють різні ліганди крові та екстрацелюлярного матриксу. ФН бере участь у різноманітних біологічних процесах, таких як клітинна міграція, диференціювання, гемостаз, опсонізація, загоєння ран, онкогенна трансформація. Зміна рівня концент­рації ФН у біологічних рідинах та його експресії у тканинах може бути інформативним показником у діагностиці різно­манітних патологічних станів.
Повний текст: (PDF, російською)

References

[1] Toyoshima K, Kimura S, Cheng J, Oda Y, Mori KJ, Saku T. High-molecular-weight fibronectin synthesized by adenoid cystic carcinoma cells of salivary gland origin. Jpn J Cancer Res. 1999;90(3):308-19.
[2] Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci. 2002;115(Pt 20):3861-3.
[3] Hampel DJ, Kottgen B, Dudenhausen JW, Kottgen E. Fetal fibronectin as a marker for an imminent (preterm) delivery. A new technique using the glycoprotein lectin immunosorbent assay. J Immunol Methods. 1999;224(1-2):31-42.
[4] Yamada K.M. Fibronectin and other cell interactive glycoproteins, New York: Plenum press 1991; p. 113.
[5] Santas AJ, Peterson JA, Halbleib JL, Craig SE, Humphries MJ, Peters DM. Alternative splicing of the IIICS domain in fibronectin governs the role of the heparin II domain in fibrillogenesis and cell spreading. J Biol Chem. 2002;277(16):13650-8.
[6] Albrecht M, Renneberg H, Wennemuth G, M?schler O, Janssen M, Aum?ller G, Konrad L. Fibronectin in human prostatic cells in vivo and in vitro: expression, distribution, and pathological significance. Histochem Cell Biol. 1999;112(1):51-61.
[7] Magnusson MK, Mosher DF. Fibronectin: structure, assembly, and cardiovascular implications. Arterioscler Thromb Vasc Biol. 1998;18(9):1363-70.
[8] Manabe R, Ohe N, Maeda T, Fukuda T, Sekiguchi K. Modulation of cell-adhesive activity of fibronectin by the alternatively spliced EDA segment. J Cell Biol. 1997;139(1):295-307.
[9] Ingham KC, Brew SA, Novokhatny VV. Influence of carbohydrate on structure, stability, and function of gelatin-binding fragments of fibronectin. Arch Biochem Biophys. 1995;316(1):235-40.
[10] Beumer S, Heijnen-Snyder GJ, IJsseldijk MJ, de Groot PG, Sixma JJ. Fibronectin in an extracellular matrix of cultured endothelial cells supports platelet adhesion via its ninth type III repeat : A comparison with platelet adhesion to isolated fibronectin. Arterioscler Thromb Vasc Biol. 2000;20(4):E16-25.
[11] Aota S, Nagai T, Yamada KM. Characterization of regions of fibronectin besides the arginine-glycine-aspartic acid sequence required for adhesive function of the cell-binding domain using site-directed mutagenesis. J Biol Chem. 1991;266(24):15938-43.
[12] Lyon M, Rushton G, Askari JA, Humphries MJ, Gallagher JT. Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin. J Biol Chem. 2000;275(7):4599-606.
[13] Yamada KM, Kennedy DW, Kimata K, Pratt RM. Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J Biol Chem. 1980;255(13):6055-63.
[14] Bultmann H, Santas AJ, Peters DM. Fibronectin fibrillogenesis involves the heparin II binding domain of fibronectin. J Biol Chem. 1998;273(5):2601-9.
[15] Burton-Wurster N, Gendelman R, Chen H, Gu DN, Tetreault JW, Lust G, Schwarzbauer JE, MacLeod JN. The cartilage-specific (V+C)- fibronectin isoform exists primarily in homodimeric and monomeric configurations. Biochem J. 1999;341 ( Pt 3):555-61.
[16] Fattorusso R, Pellecchia M, Viti F, Neri P, Neri D, Wuthrich K. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis. Structure. 1999;7(4):381-90.
[17] Marty C, Odermatt B, Schott H, Neri D, Ballmer-Hofer K, Klemenz R, Schwendener RA. Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes. Br J Cancer. 2002;87(1):106-12.
[18] Colman-Lerner A, Fischman ML, Lanuza GM, Bissell DM, Kornblihtt AR, Baranao JL. Evidence for a role of the alternatively spliced ED-I sequence of fibronectin during ovarian follicular development. Endocrinology. 1999;140(6):2541-8.
[19] Kratz E., Kiysek A., Prastowska I. Oncofetal fibronectin. Adv Clin Exp Med. 2002;9(4):377-382.
[20] Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch. 1996;429(6):311-22.
[21] Sato S, Hughes RC. Binding specificity of a baby hamster kidney lectin for H type I and II chains, polylactosamine glycans, and appropriately glycosylated forms of laminin and fibronectin. J Biol Chem. 1992;267(10):6983-90.
[22] Kottgen E, Hell B, Muller C, Kainer F, Tauber R. Developmental changes in the glycosylation and binding properties of human fibronectins. Characterization of the glycan structures and ligand binding of human fibronectins from adult plasma, cord blood and amniotic fluid. Biol Chem Hoppe Seyler. 1989;370(12):1285-94.
[23] Zhu BC, Laine RA. Developmental study of human fetal placental fibronectin: alterations in carbohydrates of tissue fibronectin during gestation. Arch Biochem Biophys. 1987;252(1):1-6.
[24] Zhu BC, Fisher SF, Pande H, Calaycay J, Shively JE, Laine RA. Human placental (fetal) fibronectin: increased glycosylation and higher protease resistance than plasma fibronectin. Presence of polylactosamine glycopeptides and properties of a 44-kilodalton chymotryptic collagen-binding domain: difference from human plasma fibronectin. J Biol Chem. 1984;259(6):3962-70.
[25] Zhu BC, Laine RA. Polylactosamine glycosylation on human fetal placental fibronectin weakens the binding affinity of fibronectin to gelatin. J Biol Chem. 1985;260(7):4041-5.
[26] Olden K, Pratt RM, Yamada KM. Role of carbohydrate in biological function of the adhesive glycoprotein fibronectin. Proc Natl Acad Sci U S A. 1979;76(7):3343-7.
[27] Jones GE, Arumugham RG, Tanzer ML. Fibronectin glycosylation modulates fibroblast adhesion and spreading. J Cell Biol. 1986;103(5):1663-70.
[28] Fukuda M, Levery SB, Hakomori S. Carbohydrate structure of hamster plasma fibronectin. Evidence for chemical diversity between cellular and plasma fibronectins. J Biol Chem. 1982;257(12):6856-60.
[29] Paul JI, Hynes RO. Multiple fibronectin subunits and their post-translational modifications. J Biol Chem. 1984;259(21):13477-87.
[30] Romanenko AM, Drannik GH, Yena YaM. Fibronectin and its role in the processes of tissue differentiation, regeneration and malignant transformation. Eksp. onkol. 1987; 9(4):8-13.
[31] Morin N, Sullivan R. Expression of fibronectin and a fibronectin-binding molecule during preimplantation development in the mouse. Hum Reprod. 1994;9(5):894-901.
[32] George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993;119(4):1079-91.
[33] Demir A.Y. Fibronectin isoforms in the extracellular matrices of human term placenta. Early Pregnancy.,2003; 6:214-234.
[34] Demir A.Y. Distribution of different fibronectin isoforms in the extracellular matrices of human term placenta. Turkish Journal of Medical Sciences, 2002; 32 (6):445-456.
[35] Matsuura H, Greene T, Hakomori S. An alpha-N-acetylgalactosaminylation at the threonine residue of a defined peptide sequence creates the oncofetal peptide epitope in human fibronectin. J Biol Chem. 1989;264(18):10472-6.
[36] Huppertz B, Kertschanska S, Frank HG, Gaus G, Funayama H, Kaufmann P. Extracellular matrix components of the placental extravillous trophoblast: immunocytochemistry and ultrastructural distribution. Histochem Cell Biol. 1996;106(3):291-301.
[37] Sebko TV, Aliyev VA. Fibronectin and pregnancy. Klinicheskaya meditsina. 1991; 2:46-9.
[38] Drannik RN, Romanenko AM, Yena YaM. Biological properties and clinical significance of plasma fibronectin. Vrachebnoye delo. 1988; 3:102-6.
[39] Yaglov VV, Loshchilov YuA, Babok AA. Role of fibronectin in the development of fibrosis. Vestnik Akademii meditsinskikh nauk SSSR. 1991; 2:50-2.
[40] Yena YaM, Konopleva LF, Chayalo AA, Sushko YeA, Shekhter IYe. Clinical value of the detection of fibronectin in internal medicine. Klinicheskaya meditsina. 1991; 2:24-30.
[41] Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ. 2002;325(7359):301.
[42] Colombo DF. Predicting spontaneous preterm birth. BMJ. 2002;325(7359):289-90.
[43] Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer. 1994;59(1):11-6.
[44] Carsons S, Clausen H, Wolf J. Expression of a developmentally regulated epitope on fibronectins from the synovial fluid of patients with rheumatic disease. J Rheumatol. 1994;21(10):1888-91.